论文部分内容阅读
目的探讨非根治性肝切除术联合索拉非尼治疗肝细胞癌的疗效及其与肿瘤组织血管内皮生长因子(VEGF)表达的关系。方法 32例肝癌患者均行非根治性切除术,术后服用索拉非尼,观察近期疗效。采用免疫组化方法检测肝癌组织VEGF的表达,评价肝癌疗效与VEGF表达的关系。结果术后转移复发24例(75.0%),死亡12例(37.5%),存活20例;复发时间为(8.33±3.95)个月,中位总生存时间(OS)为19.5个月。癌组织中VEGF阳性表达24例(75.0%),阴性表达8例(25.0%),VEGF阳性组与VEGF阴性组的中位OS分别为17.02和20.17个月,两组中位OS比较差异无统计学意义(P>0.05)。24例复发组患者中VEGF阳性表达20例(83.3%),8例未复发组患者VEGF阳性表达4例(50.0%),复发组与未复发组患者的VEGF阳性率比较,差异无统计学意义(P>0.05)。结论非根治性肝切除术联合索拉非尼治疗肝癌有一定疗效,其效果与肿瘤组织VEGF表达无关联。
Objective To investigate the curative effect of non-radical hepatectomy combined with sorafenib on hepatocellular carcinoma and its relationship with the expression of vascular endothelial growth factor (VEGF) in tumor tissue. Methods Thirty-two patients with liver cancer underwent non-radical resection and were treated with sorafenib after operation to observe the short-term curative effect. The expression of VEGF in hepatocellular carcinoma was detected by immunohistochemistry to evaluate the relationship between the curative effect of hepatocellular carcinoma and the expression of VEGF. Results Twenty - four patients (75.0%) had recurrence and metastasis after surgery, 12 (37.5%) died and 20 survived. The recurrence time was (8.33 ± 3.95) months and the median overall survival time (OS) was 19.5 months. The positive expression of VEGF in 24 cases (75.0%) and 8 cases (25.0%) were negative in VEGF-positive and VEGF-negative groups, respectively. The median OS was 17.02 and 20.17 months respectively. There was no significant difference in median OS between the two groups Significance (P> 0.05). The VEGF positive expression was found in 20 of 24 (83.3%) patients in 24 relapsed cases and in 4 of 8 non-relapsed patients (50.0%). There was no significant difference in the positive rate of VEGF among relapsed group and non-relapsed group (P> 0.05). Conclusion Non-radical hepatectomy combined with sorafenib treatment of liver cancer have a certain effect, the effect is not associated with VEGF expression in tumor tissue.